Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents (Q35551162)

8 August 2017

1 reference

title

Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents (English)

1 reference

8 August 2017

1 reference

1

Cesare Gridelli

1 reference

8 August 2017

Antonio Rossi

2

1 reference

PubMed ID

14528288

8 August 2017

Paolo Maione

series ordinal

3

1 reference

PubMed ID

14528288

8 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

8 August 2017

1 reference

8 August 2017

22

1 reference

8 August 2017

42

1 reference

8 August 2017

6629-6638

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1206957

8 August 2017

0 references

cites work

Blocking oncogenic Ras signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Influence of unrecognized molecular heterogeneity on randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Herceptest: HER2 expression and gene amplification in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Cyclooxygenase, NSAIDs, and colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Pleura mesothelioma: combined modality treatments

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Chemotherapy of non-small cell lung cancer in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Anticancer drug targets: approaching angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Clinical trial designs for cytostatic agents: are new approaches needed?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

The molecular heterogeneity of protein kinase C and its implications for cellular regulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Global cancer statistics in the year 2000.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

DNA microarrays in clinical oncology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Mechanisms of apoptosis avoidance in cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Potent and specific inhibitors of protein kinase C of microbial origin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206957

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1206957

1 reference

8 August 2017

1 reference

PubMed ID

14528288